Poster presentations will be available throughout the meeting as an on-demand session beginning at 10 a.m. EDT on Monday, August 17.

PO-01 Transcriptional dimensions provide a framework for describing tumor heterogeneity in CLL. Julie Feusier, University of Utah, Salt Lake City, UT, USA.

PO-04 Non-coding mutations in mantle cell lymphoma disrupt regulation of HNRNPH1 by alternative splicing. Krysta Coyle, Simon Fraser University, Burnaby, BC, Canada.

PO-05 TET2 deficiency alters the epigenome of germinal center B-cells, contributing to lymphoma formation. Pilar Dominguez, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.

PO-06 Ultra-deep sequencing of classical Hodgkin lymphoma (cHL) identifies recurrent somatic mutations and demonstrates the production of reproducible data from rare malignant cells. Felicia Gomez, Washington University School of Medicine, Saint Louis, MO, USA.

PO-07 The FLI1 direct target ASB2 promotes NF-kB pathway activation in diffuse large B-cell lymphoma of the germinal center B-cell type. Giulio Sartori, Institute of Oncology Research, Faculty of Biomedical Sciences, USI, Bellinzona, Switzerland.

PO-08 Understanding the properties and oncogenic mechanisms of EZH2 Y641 mutations in lymphoma. George Souroullas, Washington University School of Medicine, St. Louis, MO, USA.

PO-10 Histone 1 deficiency drives lymphoma through disruption of 3D chromatin architecture. Nevin Yusufova, Weill Cornell Medicine, New York, NY, USA.

PO-11 Targeting scavenger receptor type B1 in cholesterol-addicted lymphomas abolishes glutathione peroxidase 4 expression and results in ferroptosis. Jonathan Rink, Northwestern University, Chicago, IL, USA.


PO-13 Structural requirements for GRK2-mediated inhibition of the MALT1 proto-oncoprotein. Lisa Maurer, University of Pittsburgh, Pittsburgh, PA, USA.
Poster presentations will be available throughout the meeting as an on-demand session beginning at 10 a.m. EDT on Monday, August 17.

PO-17 Microphysiological model of ALK+ anaplastic large cells lymphoma and vascular interactions predicts drug efficacy in a 3D microfluidic chip. Marco Campisi, Politecnico di Torino, Turin, Italy.


PO-19 Sequential inverse dysregulation of the RNA helicases DDX3X and DDX3Y facilitates MYC-driven lymphomagenesis. Daniel Hodson, University of Cambridge, Cambridge, UK.

PO-20 Molecular characterization of a mouse model of peripheral T cell lymphoma with Tfh and Th2 features. Elizabeth Kuczynski, AstraZeneca, Cambridge, UK.

PO-21 Investigating the role of exosomes derived from chemotherapy-resistant leukemia cells as mediators of cellular plasticity. Taismara Kustro Garnica, University of São Paulo, Pirassununga, São Paulo, Brazil.

PO-22 Compromised counterselection by FAS creates a lethal subtype of germinal center lymphoma. Jagan Muppidi, National Cancer Institute, Bethesda, MD, USA.

PO-23 Somatic hypermutation is perturbed in ABC-DLBCL lymphoma cell lines expressing high levels of activation-induced deaminase. Huseyin Saribasak, Yale University School of Medicine, New Haven, CT, USA.

PO-24 Modeling marginal zone lymphomagenesis. Victor Yazbeck, Massey Cancer Center, Richmond, VA, USA.

PO-25 CLR 131 demonstrates 100% overall response rate in relapsed or refractory Lymphoplasmacytic Lymphoma (LPL)/Waldenstrom’s Macroglobulinemia (WM): Initial results from ongoing Phase 2 trial, CLOVER-1 study. Jarrod Longcor, Cellectar Biosciences, Florham Park, NJ, USA.

PO-26 Prognostic significance of Fc gamma receptor IIB expression in the response of previously untreated diffuse large B-cell lymphomas to anti-CD20 monoclonal antibodies: Differing impact of rituximab and obinutuzumab. Laura K. Hilton, BC Cancer Centre for
Poster presentations will be available throughout the meeting as an on-demand session beginning at 10 a.m. EDT on Monday, August 17.

Lymphoid Cancer, Vancouver and Canada’s Michael Smith Genome Sciences Centre, Vancouver, BC, Canada.

**PO-27 Clonotypic cell-free DNA (cfDNA) in the cerebrospinal fluid (CSF) of patients with aggressive lymphomas.** Adam Olszewski, Warren Alpert Medical School of Brown University, Providence, RI, USA.

**PO-28 Anti-tumor effects of cannabinoids against B-cell lymphoma.** Saba Omer, Auburn University, Auburn, AL, USA.

**PO-29 Conserved and unique transcriptional programs in human and canine non-Hodgkin lymphomas inform the judicious applications for the spontaneous canine model of disease.** Aaron Sarver, University of Minnesota, Minneapolis, MN, USA.

**PO-30 Is it more explanatory to integrate the leukocyte/lymphocyte ratio (LLR) and prognostic nutritional index (PNI) to international prognostic systems (IPS) in cases with Hodgkin lymphoma (HL).** Semra Paydas, Cukurova University, Adana, Turkey.

**PO-31 HIV-1 transactivator of transcription deregulates key Burkitt lymphoma–associated oncogenes at both the transcriptional and posttranscriptional level.** Leonardo Alves de Souza Rios, University of Cape Town, Cape Town, Western Cape Province, South Africa.

**PO-32 NFKBIZ 3’ UTR mutations confer selective growth advantage and affect drug response in diffuse large B-cell lymphoma.** Sarah Arthur, Simon Fraser University, Burnaby, BC, Canada.

**PO-34 Subcutaneous panniculitis-like T-cell lymphoma with HAVCR2 mutation shows unique clinicopathological features and gene expression profile.** Yoon Kyung Jeon, Seoul National University College of Medicine, Seoul, Republic of Korea.

**PO-35 Prognostic significance of MYC, BCL2, and BCL6 co-localization at single-cell resolution in DLBCL.** Anand Jeyasekharan, Cancer Science Institute of Singapore, National University of Singapore, National University Health System, Singapore, Singapore.

**PO-36 Functional bypass of cell cycle entry checkpoints by MYC T58A mutation in germinal center-derived lymphomas.** Jongkuen Lee, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Poster presentations will be available throughout the meeting as an on-demand session beginning at 10 a.m. EDT on Monday, August 17.

PO-38 Genomic subtypes correlate with the risk of central nervous system (CNS) recurrence in diffuse large B-cell lymphoma (DLBCL). Adam Olszewski, Warren Alpert Medical School of Brown University, Providence, RI, USA.

PO-40 FOXO1 mutations mimic positive selection signals to promote germinal center B cell expansion and lymphomagenesis. Mark Roberto, Icahn School of Medicine at Mount Sinai, New York, NY, USA.

PO-41 Expression of Vav1-Myo1F fusion affects T-cell differentiation and induces T-cell lymphoma. Jose Rodriguez Cortes, Columbia University, New York, NY, USA.

PO-42 TBL1XR1 mutations drive extranodal lymphomagenesis by inducing a pro-tumorigenic memory B-cell fate. Leandro Venturutti, Weill Cornell Medicine, New York, NY, USA.

PO-43 Targeting DNA repair in EZH2 gain-of-function diffuse large B-cell lymphoma. Srividya Bhaskara, Huntsman Cancer Institute, Salt Lake City, UT, USA.

PO-44 Past infection and risk of adolescent/young adult HL. Wendy Cozen, Keck School of Medicine of University of Southern California, Los Angeles, CA, USA.

PO-45 Robust detection of translocations in lymphoma FFPE samples using Targeted Locus Capture-based sequencing. Arjan Diepstra, University Medical Centre Groningen, Groningen, Netherlands.

PO-46 Mechanisms of resistance to the PI3K inhibitor copanlisib in marginal zone lymphoma. Alberto Arribas, Institute of Oncology Research, USI, Bellinzona, Switzerland.

PO-47 BTM-3566 induces complete tumor regression in diffuse large B-cell lymphoma: Regulation by the elf2α kinase ‘heme regulated Inhibitor’ and the mitochondrial protein FAM210B. Jedd Levine, Bantam Pharmaceutical, New York, NY, USA.

PO-48 Cytotoxic mechanism of a novel transferrin receptor-targeting chemotherapeutic nanocarrier for use in diffuse large B-cell lymphoma. Artavazd Arumov, University of Miami Miller School of Medicine, Miami, FL, USA.
Poster presentations will be available throughout the meeting as an on-demand session beginning at 10 a.m. EDT on Monday, August 17.

**PO-49 Discovery of JNJ-67856633: A novel, first-in-class MALT1 protease inhibitor for the treatment of B cell lymphomas.** Ulrike Philippar, Janssen R&D, Beerse, Belgium.

**PO-50 Phophatases modulate resistance to ALK inhibitors in anaplastic large-cell lymphoma.** Roberto Chiarle, Department of Pathology, Boston Children’s Hospital, Harvard Medical School, Boston, MA, USA.

**PO-51 Drug combination analytics platform for accurate prediction of treatment response in refractory and relapsed lymphomas.** Edward Chow, National University of Singapore, Singapore, Singapore.

**PO-52 Durable and excellent response in patient with Richter’s transformation and del 17p treated with ibrutinib and venetoclax.** John McKay, Virginia Commonwealth University, Richmond, VA, USA.

**PO-53 Combined EZH2 and BCL2 inhibitors as precision therapy for genetically defined DLBCL subtypes.** Hanna Scholze, Weill Cornell Medical College, New York, NY, USA.

**PO-54 Mechanistic consequences of histone-deacetylase inhibition towards sensitizing PD1-blockade-resistant B cell lymphomas.** Jing Wang, University of Colorado Anschutz Medical Campus, Aurora, CO, USA.

**PO-55 Single center experience of Chimeric Antigen Receptor T-cell (CAR-T) immunotherapy in relapsed/refractory large B-cell lymphoma identifies association of acute toxicities with inferior disease outcomes.** Caroline Coughlin, University of Miami Miller School of Medicine, Miami, FL, USA.

**PO-56 Identification of predicted neoantigen vaccine candidates in follicular lymphoma patients.** Cody Ramirez, Washington University School of Medicine in St. Louis, St. Louis, MO, USA.

**PO-57 Association between cytokine levels and prolonged cytopenia after axicabtagene ciloleucel in patients with refractory large B-cell lymphoma.** Paolo Strati, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Poster presentations will be available throughout the meeting as an on-demand session beginning at 10 a.m. EDT on Monday, August 17.

PO-58 Obinutuzumab plus chemotherapy is cost-effective versus rituximab biosimilars plus chemotherapy for previously untreated follicular lymphoma patients. David Veenstra, University of Washington Department of Pharmacy, Seattle, WA, USA.

PO-59 Anti-membrane IgM monoclonal antibody, mAb4, is a novel, next generation BTK inhibitor mediating B-cell leukemia and lymphoma cell death. Rachel Welt, Welt Bio-Molecular Pharmaceutical, Briarcliff Manor, NY, USA.

PO-60 The stage-specific roles of radiotherapy and chemotherapy in nodular lymphocyte predominant Hodgkin lymphoma patients: A propensity matched analysis of the Surveillance, Epidemiology, and End Results database. Zhenming Fu, Renmin Hospital of Wuhan University, Wuhan, China.

PO-61 Rethinking radiation therapy in the modern era of advanced systemic treatments of malignant lymphoma. Lena Specht, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.

PO-62 Overcoming venetoclax resistance in B cell malignancies by antagonism of stromal TGF-beta mediated drug resistance. Ingo Ringshausen, University of Cambridge Stem Cell Institute, Cambridge, Cambridgeshire, United Kingdom.

PO-63 A phase 2a open-label study of MT-3724, a novel CD20-targeting engineered toxin body, in combination with lenalidomide (LEN) in subjects with relapsed or refractory B-cell non-Hodgkin lymphoma (NHL). Thomas Strack, Molecular Templates, Inc., Jersey City, NJ, USA.